Use of Wild Type or Recombinant Lactic Acid Bacteria as an Alternative Treatment for Gastrointestinal Inflammatory Diseases: A Focus on Inflammatory Bowel Diseases and Mucositis
The human gastrointestinal tract (GIT) is highly colonized by bacterial communities, which live in a symbiotic relationship with the host in normal conditions. It has been shown that a dysfunctional interaction between the intestinal microbiota and the host immune system, known as dysbiosis, is a ve...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2017-05-01
|
| Series: | Frontiers in Microbiology |
| Subjects: | |
| Online Access: | http://journal.frontiersin.org/article/10.3389/fmicb.2017.00800/full |
| _version_ | 1818110389021310976 |
|---|---|
| author | Rodrigo D. De Oliveira Carvalho Fillipe L. R. do Carmo Alberto de Oliveira Junior Philippe Langella Jean-Marc Chatel Luis G. Bermúdez-Humarán Vasco Azevedo Marcela S. de Azevedo |
| author_facet | Rodrigo D. De Oliveira Carvalho Fillipe L. R. do Carmo Alberto de Oliveira Junior Philippe Langella Jean-Marc Chatel Luis G. Bermúdez-Humarán Vasco Azevedo Marcela S. de Azevedo |
| author_sort | Rodrigo D. De Oliveira Carvalho |
| collection | DOAJ |
| description | The human gastrointestinal tract (GIT) is highly colonized by bacterial communities, which live in a symbiotic relationship with the host in normal conditions. It has been shown that a dysfunctional interaction between the intestinal microbiota and the host immune system, known as dysbiosis, is a very important factor responsible for the development of different inflammatory conditions of the GIT, such as the idiopathic inflammatory bowel diseases (IBD), a complex and multifactorial disorder of the GIT. Dysbiosis has also been implicated in the pathogenesis of other GIT inflammatory diseases such as mucositis usually caused as an adverse effect of chemotherapy. As both diseases have become a great clinical problem, many research groups have been focusing on developing new strategies for the treatment of IBD and mucositis. In this review, we show that lactic acid bacteria (LAB) have been capable in preventing and treating both disorders in animal models, suggesting they may be ready for clinical trials. In addition, we present the most current studies on the use of wild type or genetically engineered LAB strains designed to express anti-inflammatory proteins as a promising strategy in the treatment of IBD and mucositis. |
| first_indexed | 2024-12-11T02:46:22Z |
| format | Article |
| id | doaj.art-7a557d32d9cc4eed8c996c3c0f9e5e54 |
| institution | Directory Open Access Journal |
| issn | 1664-302X |
| language | English |
| last_indexed | 2024-12-11T02:46:22Z |
| publishDate | 2017-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Microbiology |
| spelling | doaj.art-7a557d32d9cc4eed8c996c3c0f9e5e542022-12-22T01:23:26ZengFrontiers Media S.A.Frontiers in Microbiology1664-302X2017-05-01810.3389/fmicb.2017.00800258792Use of Wild Type or Recombinant Lactic Acid Bacteria as an Alternative Treatment for Gastrointestinal Inflammatory Diseases: A Focus on Inflammatory Bowel Diseases and MucositisRodrigo D. De Oliveira Carvalho0Fillipe L. R. do Carmo1Alberto de Oliveira Junior2Philippe Langella3Jean-Marc Chatel4Luis G. Bermúdez-Humarán5Vasco Azevedo6Marcela S. de Azevedo7Federal University of Minas Gerais – Instituto de Ciências BiológicasBelo Horizonte, BrazilFederal University of Minas Gerais – Instituto de Ciências BiológicasBelo Horizonte, BrazilFederal University of Minas Gerais – Instituto de Ciências BiológicasBelo Horizonte, BrazilMicalis Institute, Institut National de la Recherche Agronomique, AgroParisTech, Université Paris-SaclayJouy-en-Josas, FranceMicalis Institute, Institut National de la Recherche Agronomique, AgroParisTech, Université Paris-SaclayJouy-en-Josas, FranceMicalis Institute, Institut National de la Recherche Agronomique, AgroParisTech, Université Paris-SaclayJouy-en-Josas, FranceFederal University of Minas Gerais – Instituto de Ciências BiológicasBelo Horizonte, BrazilFederal University of Minas Gerais – Instituto de Ciências BiológicasBelo Horizonte, BrazilThe human gastrointestinal tract (GIT) is highly colonized by bacterial communities, which live in a symbiotic relationship with the host in normal conditions. It has been shown that a dysfunctional interaction between the intestinal microbiota and the host immune system, known as dysbiosis, is a very important factor responsible for the development of different inflammatory conditions of the GIT, such as the idiopathic inflammatory bowel diseases (IBD), a complex and multifactorial disorder of the GIT. Dysbiosis has also been implicated in the pathogenesis of other GIT inflammatory diseases such as mucositis usually caused as an adverse effect of chemotherapy. As both diseases have become a great clinical problem, many research groups have been focusing on developing new strategies for the treatment of IBD and mucositis. In this review, we show that lactic acid bacteria (LAB) have been capable in preventing and treating both disorders in animal models, suggesting they may be ready for clinical trials. In addition, we present the most current studies on the use of wild type or genetically engineered LAB strains designed to express anti-inflammatory proteins as a promising strategy in the treatment of IBD and mucositis.http://journal.frontiersin.org/article/10.3389/fmicb.2017.00800/fullinflammatory bowel diseasesmucositislactic acid bacteriaLactococcus lactisgenetic engineering |
| spellingShingle | Rodrigo D. De Oliveira Carvalho Fillipe L. R. do Carmo Alberto de Oliveira Junior Philippe Langella Jean-Marc Chatel Luis G. Bermúdez-Humarán Vasco Azevedo Marcela S. de Azevedo Use of Wild Type or Recombinant Lactic Acid Bacteria as an Alternative Treatment for Gastrointestinal Inflammatory Diseases: A Focus on Inflammatory Bowel Diseases and Mucositis Frontiers in Microbiology inflammatory bowel diseases mucositis lactic acid bacteria Lactococcus lactis genetic engineering |
| title | Use of Wild Type or Recombinant Lactic Acid Bacteria as an Alternative Treatment for Gastrointestinal Inflammatory Diseases: A Focus on Inflammatory Bowel Diseases and Mucositis |
| title_full | Use of Wild Type or Recombinant Lactic Acid Bacteria as an Alternative Treatment for Gastrointestinal Inflammatory Diseases: A Focus on Inflammatory Bowel Diseases and Mucositis |
| title_fullStr | Use of Wild Type or Recombinant Lactic Acid Bacteria as an Alternative Treatment for Gastrointestinal Inflammatory Diseases: A Focus on Inflammatory Bowel Diseases and Mucositis |
| title_full_unstemmed | Use of Wild Type or Recombinant Lactic Acid Bacteria as an Alternative Treatment for Gastrointestinal Inflammatory Diseases: A Focus on Inflammatory Bowel Diseases and Mucositis |
| title_short | Use of Wild Type or Recombinant Lactic Acid Bacteria as an Alternative Treatment for Gastrointestinal Inflammatory Diseases: A Focus on Inflammatory Bowel Diseases and Mucositis |
| title_sort | use of wild type or recombinant lactic acid bacteria as an alternative treatment for gastrointestinal inflammatory diseases a focus on inflammatory bowel diseases and mucositis |
| topic | inflammatory bowel diseases mucositis lactic acid bacteria Lactococcus lactis genetic engineering |
| url | http://journal.frontiersin.org/article/10.3389/fmicb.2017.00800/full |
| work_keys_str_mv | AT rodrigoddeoliveiracarvalho useofwildtypeorrecombinantlacticacidbacteriaasanalternativetreatmentforgastrointestinalinflammatorydiseasesafocusoninflammatoryboweldiseasesandmucositis AT fillipelrdocarmo useofwildtypeorrecombinantlacticacidbacteriaasanalternativetreatmentforgastrointestinalinflammatorydiseasesafocusoninflammatoryboweldiseasesandmucositis AT albertodeoliveirajunior useofwildtypeorrecombinantlacticacidbacteriaasanalternativetreatmentforgastrointestinalinflammatorydiseasesafocusoninflammatoryboweldiseasesandmucositis AT philippelangella useofwildtypeorrecombinantlacticacidbacteriaasanalternativetreatmentforgastrointestinalinflammatorydiseasesafocusoninflammatoryboweldiseasesandmucositis AT jeanmarcchatel useofwildtypeorrecombinantlacticacidbacteriaasanalternativetreatmentforgastrointestinalinflammatorydiseasesafocusoninflammatoryboweldiseasesandmucositis AT luisgbermudezhumaran useofwildtypeorrecombinantlacticacidbacteriaasanalternativetreatmentforgastrointestinalinflammatorydiseasesafocusoninflammatoryboweldiseasesandmucositis AT vascoazevedo useofwildtypeorrecombinantlacticacidbacteriaasanalternativetreatmentforgastrointestinalinflammatorydiseasesafocusoninflammatoryboweldiseasesandmucositis AT marcelasdeazevedo useofwildtypeorrecombinantlacticacidbacteriaasanalternativetreatmentforgastrointestinalinflammatorydiseasesafocusoninflammatoryboweldiseasesandmucositis |